...cleared bacterial burden in mouse models of sepsis, pneumonia and urinary tract infection comparable to tigecycline...

...disease INDICATION: Gram-negative bacterial infection A computationally designed 20-amino acid peptide could treat carbapenem- and tigecycline-resistant...
...tigecycline-resistant A. baumannii infection, compared with a rate of 12.5% for meropenem and 0% for tigecycline...

...with confirmed CRE infections. It compared Zemdri to colistin on a background of meropenem or tigecycline...
...therapy was permitted for up to 72 hours. In addition, adjunctive therapy with meropenem or tigecycline...

...Tygacil tigecycline decreased proliferation, colony formation, mitochondrial respiration and oxidative phosphorylation compared with vehicle, and Tygacil...
...and colony formation compared with either agent alone. In a xenograft mouse model of CML, Tygacil...
...BCR-ABL) inhibitor Gleevec for CML and several other hematologic malignancies and cancers. Pfizer Inc. markets Tygacil...

...of the open-label, international Phase III CARE trial showed that IV plazomicin plus meropenem or tigecycline...
...the primary endpoint, vs. 50% for colistin plus meropenem or tigecycline. Plazomicin plus meropenem or tigecycline...
...to a 28-day all-cause mortality rate of 11.8% vs. 40% for colistin plus meropenem or tigecycline...

...CARE trial comparing IV plazomicin plus meropenem or tigecycline vs. IV colistin plus meropenem or tigecycline...

...patents for rosacea drug Oracea doxycycline from Galderma S.A. , Pfizer Inc .'s antibiotic Tygacil tigecycline...

...Date IPR filed Mcap change week of Mcap change to 5/15 Pfizer Inc. (NYSE:PFE) Tygacil tigecycline...

...III trial comparing IV plazomicin plus meropenem or tigecycline vs. IV colistin plus meropenem or tigecycline...
...2006 (see BioCentury, Feb. 6, 2006). Pfizer Inc. (NYSE:PFE, New York, N.Y. ) markets Tygacil tigecycline...

...Therapeutics' pipeline includes two Phase I programs and two preclinical stem cell programs. The company's tigecycline...